Table 1. IC₅₀ Values (μM) of 1–3, BMS-001, PARPi, and Olaparib against a Panel of Cancer Cell Lines after 7 Days of Exposure^a.

cell line	1	2	3	BMS-001	PARPi	olaparib
OVCAR8	13.62 ± 1.7	5.02 ± 0.3	6.29 ± 1.9	25.53 ± 0.15	25.5 ± 00.1	11.14 ± 5.4
MDA-MB-231	10.99 ± 6.7	9.51 ± 7.5	5.89 ± 5.6	14.83 ± 7.7	26.61 ± 1.13	14.00 ± 7.1
A2780	12.68 ± 8.6	5.82 ± 10.2	5.40 ± 3.42	24.26 ± 10.2	25.68 ± 8.4	9.32 ± 0.2
SKOV3	3.8 ± 34.48	5.13 ± 6.1	12.17 ± 0.43	24.36 ± 2.31	50.0 ± 70.1
H460	13.6 ± 0.2	10.64 ± 0.48	5.91 ± 0.13	21.49 ± 0.19	28.57 ± 0.82	8.1 ± 1.2
HCC1937	10.79 ± 0.4	10.67 ± 0.59	5.26 ± 0.05	13.54 ± 0.11	20.77 ± 0.17	18.44 ± 2.4

^aCompounds were freshly prepared in DMSO and used immediately. DMSO concentration was <1%.